Medicine and Pharmacy Reports最新文献

{"title":"New prospects in oncotherapy: bioactive compounds from <i>Taraxacum officinale</i>.","authors":"Daniel Cord, Mirela Claudia Rîmbu, Liliana Popescu","doi":"10.15386/mpr-2875","DOIUrl":"10.15386/mpr-2875","url":null,"abstract":"<p><p>Cancer remains one of the most significant global health challenges, requiring continuous exploration of novel therapeutic agents. Traditional medicine has long used <i>Taraxacum officinale H.Wigg</i>, commonly known as dandelion, for its diverse pharmacological properties. Recent studies have highlighted its potential anticancer effects attributed to a rich phytochemical profile containing flavonoids, terpenoids, phenolic acids, polysaccharides, and sterols. This review systematically examines the available scientific literature regarding <i>Taraxacum officinale</i>, focusing on its ethnomedical application, phytochemical composition, and anticancer mechanism demonstrated <i>in vitro</i> and <i>in vivo</i> models. Key bioactive compounds, such as taraxasterol, chlorogenic acid, chicoric acid, and taraxinic acid, have been identified as promising agents capable of inhibiting tumor cell proliferation and modulating oncogenic pathways. Additionally, the plant's safety profile and toxicological assessments are discussed to evaluate its therapeutic viability. Given its multi-target biological activity and low toxicity, <i>Taraxacum officinale</i> holds significant potential for integration into oncotherapy as an adjuvant treatment. However, further preclinical and clinical investigations remain essential to validate its efficacy and mechanism of action, paving the way for the development of cost-effective, plant-based cancer therapeutics.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"290-299"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of steroids and antiviral agents in the treatment of Bell's palsy.","authors":"Christos Sialakis, Aikaterini Frantzana, Christos Iliadis, Peter Ouzounakis, Lambrini Kourkouta","doi":"10.15386/mpr-2786","DOIUrl":"10.15386/mpr-2786","url":null,"abstract":"<p><strong>Background: </strong>This study aims to investigate the effectiveness of steroids plus antivirals versus steroids alone in the treatment of Bell's palsy. Due to conflicting results in the existing literature, we conducted this meta-analysis to synthesize the available evidence and extract a more complete conclusion.</p><p><strong>Methods: </strong>We searched electronic databases PubMed, CINAHL, ScienceDirect, MEDLINE, OVID, and Scopus. The last search was performed on March 2024. In this study, 7 randomized controlled trials were included. We used random and fixed effects for sensitivity analysis for each outcome, and we further proceeded to perform a Bayesian meta-analysis using priors and calculate the posterior distribution.</p><p><strong>Results: </strong>Performing frequentist meta-analysis, both the random and fixed effects showed statistical significance, indicating the superiority of the combination treatment. The random log odds ratio was 0.5865 [95% CI: 0.0141 to 1.1589 and the Back-Transform Log Odds Ratio to Odds Ratio was 1.798 [95% CI: 1.014 to 3.186]. The fixed effect log odds ratio was 0.4377 [95%CI: 0.0819 to 0.7934] and the Back-Transform Log Odds Ratio to Odds Ratio was 1.549 [95% CI:1.085 to 2.211]. Neither the rank correlation nor the regression test in both models indicated any funnel plot asymmetry and publication bias.Performing Bayesian meta-analysis, in the posterior distribution the model-averaged log odds ratio was 0.26 [0.00 to 0.90], showing no statistically significant results, as the log odds ratio contains the zero. The inclusion Bayes Factor (BF) for the effect was 1.225 showing anecdotal supporting evidence for the combination treatment. The inclusion BF for the heterogeneity was 0.979, showing no support for its existence in the analysis and the inclusion BF for the publication bias was 0.622, a lower of 1, indicating evidence of its absence in the analysis.</p><p><strong>Conclusions: </strong>The combination of steroids plus an antiviral agent, is more efficacious than steroid monotherapy in treating Bell's palsy. This conclusion is supported by frequentist analysis, but not by the Bayesian approach as the Bayesian meta-analysis was inconclusive, suggesting some uncertainty in the effect size but this could be due to priors influence. Further research with advanced syntheses such as network and Bayesian meta-analysis is needed as well as more double-blinded randomized controlled trials.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"267-282"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between metabolic syndrome and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: a cross-sectional study.","authors":"Abdessamad Malki, Imane Assarrar, Imane Ziani, Fatim Zahra Bentebbaa, Nisrine Bouichrat, Siham Rouf, Hanane Latrech","doi":"10.15386/mpr-2779","DOIUrl":"10.15386/mpr-2779","url":null,"abstract":"<p><strong>Background and aims: </strong>Diabetic peripheral neuropathy (DPN) is the most prevalent chronic complication of diabetes. Several risk factors have been identified in recent studies, in particular metabolic syndrome (MetS). However, this association remains unclear. We aimed to determine the prevalence of DPN and to study its associated factors, especially the MetS as a potential risk factor of DPN in patients with Type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>This was a retrospective and comparative study, with cross-sectional collected data, involving patients with T2DM from North Africa, followed up in the Department of Endocrinology-Diabetology-Nutrition at Mohammed VI University Hospital Center of Oujda, located in the eastern region of Morocco. Patients were grouped according to the presence (T2DM/DPN+, n = 110) or absence of DPN (T2DM/DPN-, n = 290). Data were collected from medical records and analyzed using SPSS software version 21.</p><p><strong>Results: </strong>DPN was found in 27.5% of the patients. The mean age was similar between the two groups, at 58.96 ± 11.86 years in the T2DM/DPN+ group and 57.10 ± 13.29 years in the T2DM/DPN- group. Males comprised 40.9% of the T2DM/DPN+ group and 31.7% of the T2DM/DPN- group, but this difference was not statistically significant (p = 0.054). Patients with DPN had a significantly longer duration of diabetes (median 10 years vs. 5 years, p < 0.001). Both groups showed glycemic imbalance, with mean HbA1c values of 10.71 ± 2.31% for T2DM/DPN+ and 10.40 ± 2.87% for T2DM/DPN-, without a significant difference. MetS was a significant predictor of neuropathy presence. The prevalence of DPN was greater in individuals with hypertension (p = 0.013), abdominal obesity (p = 0.010), elevated triglyceride levels (p = 0.007), and low HDLc (p = 0.013). Male sex and the duration of diabetes were found to be significant risk factors for the development of DPN.</p><p><strong>Conclusion: </strong>MetS and its components are strongly associated with the presence of DPN in patients with T2DM. Therefore, screening and optimal control of these risk factors may help prevent DPN in these patients. However, further intervention studies are needed to determine whether comprehensive multifactorial control in patients with T2DM and MetS can effectively prevent DPN.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"342-348"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between proton pump inhibitors and anti-coagulants for a better prevention of gastrointestinal bleeding.","authors":"Fahad Mudhi Alotaibi, Nasser Faihan Alotaibi, Faisal Farraj Alsubaie, Hussain Ali Ekhuraidah, Mohammed Ahmed Koshan, Rayan Hassan Alzahrani, Hamdan Saleh Alghamdi, Abed Houmod Allehibi, Abdulrahman Abdullah Aljumah","doi":"10.15386/mpr-2767","DOIUrl":"10.15386/mpr-2767","url":null,"abstract":"<p><strong>Background and aim: </strong>Gastrointestinal bleeding (GIB) is one of the most common medical emergencies. Proton pump inhibitors (PPI) are among the most widely used drugs in gastroenterology to treat various types of acid-related disorders. We aim to investigate the safety of proton pump inhibitors (PPIs) when used concurrently with anticoagulants in patients with upper and lower gastrointestinal bleeding (GIB) and assess the risk of hospitalization, GIB, and mortality in patients receiving this combined treatment.</p><p><strong>Methods: </strong>A retrospective multicenter study was conducted at two tertiary care hospitals. Patients were selected according to inclusion and exclusion criteria. Demographic data, vital signs, medical history, physical examinations, comorbid conditions, medications, laboratory investigations, endoscopy findings, management, and complications were retrieved from the medical records of all participants.Data obtained from all patients' medical records were reviewed. Endoscopic findings and management of the bleeding site were collected according to the presenting symptoms. Statistical analyses were performed using IBM SPSS version 25.0 software.</p><p><strong>Results: </strong>Our results revealed a significant increase in acute GIB risk with the number of concurrent anticoagulants used, particularly in patients not using PPIs. Those using four anticoagulants along with PPIs had a lower likelihood of acute GIB at 6.3% (P = 0.0001). Patients taking two or three anticoagulants also experienced reduced GIB risk when PPIs were added (P ≤ 0.05). Age played a role, with a statistically significant difference between PPI users and non-users, especially in the 31-40 age group, where PPI users had a higher incidence of GIB (69.80%) compared to non-users (30.20%) (P < 0.05). Comparing patients on anticoagulants with or without PPIs, the study found a lower risk of hospitalization (adjusted hazard ratio, AHR: 1.02; 95% CI: 0.92-1.57) and mortality (AHR: 1.00; 95% CI: 0.84-1.11) in those using Rivaroxaban and PPIs concurrently. By contrast, patients using Rivaroxaban alone without PPIs faced an increased risk of hospitalization (AHR: 1.15; 95% CI: 0.98-2.35) and mortality (AHR: 1.12; 95% CI: 0.90-1.37).</p><p><strong>Conclusions: </strong>Combining PPIs with anticoagulant drugs reduced the risk of GIB, hospitalization, and mortality, particularly in older adults, thereby mitigating potential complications.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"333-341"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing immunization gaps in children with congenital heart disease - a narrative review.","authors":"Diana Jecan-Toader, Cristina Filip, Simona Sorana Căinap","doi":"10.15386/mpr-2814","DOIUrl":"10.15386/mpr-2814","url":null,"abstract":"<p><p>Vaccination programs have had a pivotal part in the successful reduction of global morbidity and mortality of infectious diseases. Despite their undeniable success, vaccination rates among children with congenital heart disease (CHD) remain suboptimal. This article aims to address the challenges surrounding immunization in CHD patients and provide guidance for immunization practices within this population. Most experts advocate for adherence to standard immunization practices in CHD patients who are immunocompetent and in good health. Supplemental vaccinations against rotavirus, varicella, meningococcus, hepatitis A and influenza are recommended. RSV prophylaxis with palivizumab is advisable in patients with hemodynamically significant CHD during winter season. However, special considerations are warranted in specific situations, such as around cardiac surgery or in patients who are immunocompromised. Furthermore, adjustments to the vaccination schedule might be necessary for patients who require antithrombotic prophylaxis or blood transfusions. Lastly, special attention should be given to individuals at a high risk of decompensation after immunization, who might require close parental or medical monitoring for up to 72 hours post-vaccination.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"283-289"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic cancer: a persistently challenging prognosis - a single center three-year retrospective study.","authors":"Paul-Cristian Borz, Mihnea-Bogdan Borz, Oliviu-Cristian Borz, Toader Zaharie, Claudia Hagiu, Lidia Munteanu, Ana Maria Fit, Simona Gurzu","doi":"10.15386/mpr-2848","DOIUrl":"10.15386/mpr-2848","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related mortality due to its aggressive progression and late diagnosis. Despite advances in diagnosis and treatment, survival outcomes remain poor, with a median survival of 5.8 months.</p><p><strong>Objective: </strong>The aim of the study is to evaluate the impact of diagnostic and therapeutic approaches on survival outcomes in patients with pancreatic adenocarcinoma, while also assessing the risk factors for PDAC.</p><p><strong>Methods: </strong>This study is a retrospective analysis of 68 patients with suspected pancreatic tumors who underwent endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) between 2019 and 2022 at the Cluj-Napoca County Emergency Clinical Hospital. Patient demographics, risk factors, histopathological results, and treatment outcomes were analyzed using statistical methods.</p><p><strong>Results: </strong>Of 68 patients, 35 were diagnosed with PDAC. Modifiable risk factors, such as alcohol and smoking, alongside non-modifiable factors like age and hereditary predisposition, were prominent. Among PDAC patients, 42.8% received palliative chemotherapy, while only 8.6% underwent curative surgical intervention due to advanced disease stages. Median survival varied significantly based on treatment: 2.4 months for untreated patients versus 8.1 months for those receiving oncological or surgical management (p=0.0082).</p><p><strong>Conclusion: </strong>Modifiable and non-modifiable risk factors significantly raise the incidence of pancreatic cancer. Therefore, employing a multidisciplinary approach to detect the disease in its early stages and optimize personalized treatment plans can enhance patient outcomes. At the same time, traditional oncological treatments improve survival and quality of life, but newer approaches, such as immunotherapy combined with conventional radiotherapy, chemotherapy, molecular targeted therapy, and other diverse treatment modalities, have the potential to further extend survival.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"325-332"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of hardness and microroughness of injection-molded thermoplastic resins used for flexible removable partial dentures.","authors":"Roxana Diana Vasiliu, Anamaria Matichescu, Sorin Daniel Porojan, Diana Uţu, Liliana Porojan","doi":"10.15386/mpr-2849","DOIUrl":"10.15386/mpr-2849","url":null,"abstract":"<p><strong>Background and aim: </strong>This study evaluates and compares three types of thermoplastic resins used for flexible, removable partial dentures, focusing on their microhardness and surface roughness.</p><p><strong>Methods: </strong>Thirty samples with a thickness of 2 mm were obtained from thermoplastic resins and were tested after 24 hours of immersion in distilled water. The samples were obtained from injected resin cartridges of three thermoplastic resins with different degrees of flexibility. Two-way ANOVA and Tukey tests were performed to compare the samples. A Pearson correlation was calculated between the two parameters, surface roughness and Vickers microhardness.</p><p><strong>Results: </strong>After statistical analysis, significant differences were found between the two resins' surface roughness. Regarding Vickers microhardness, one of the resins with the lowest flexibility range exhibited higher microhardness values.</p><p><strong>Conclusions: </strong>Surface roughness values for the three resins were below 0.2 microns. Microhardness test revealed significant differences between Flaxiacryl and Flexifast samples (p<.05).</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"387-391"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early cognitive and quality of life changes after transfemoral transcatheter aortic valve replacement.","authors":"Mihnea Istrate, Mihaela Ioana Dregoesc, Victor Stefan Buiga, Julien Redfern, Adrian Corneliu Iancu","doi":"10.15386/mpr-2885","DOIUrl":"10.15386/mpr-2885","url":null,"abstract":"<p><strong>Background and aims: </strong>Cognitive impairment has been associated with the presence of severe aortic stenosis (AS). Our study evaluated the early changes in cognitive function and quality of life in patients with severe AS who underwent transfemoral transcatheter aortic valve replacement (TAVR).</p><p><strong>Methods: </strong>The cognitive function and quality of life of patients with severe symptomatic AS who underwent transfemoral TAVR were assessed with the Montreal Cognitive Assessment (MoCA) and the EQ-5D-3L questionnaire, respectively. The tests were performed at the time of admission and at 48 to 72 h after TAVR.</p><p><strong>Results: </strong>The study group included 37 patients with a mean age of 78 years. Cognitive improvement was observed in 72.9% of patients. A higher MoCA score at baseline was correlated with a better functional outcome after TAVR (r=0.49, p=0.02). Patients with an early post-procedural increase in MoCA scores had a smaller aortic valve area at baseline as compared to patients without cognitive improvement (0.5±0.2 vs. 0.7±0.1 sq.cm, p=0.02). The baseline aortic valve area was associated with an increase in MoCA scores at an optimal cutoff value ≤0.65 sq.cm (AUC 0.739; p=0.005). A significant increase in median EQ-5D-3L scores was observed between baseline and follow-up (60 (51-70) vs. 73 (65-80) points, p<0.001). The lack of improvement in functional status was associated with a prolonged stay in the Intensive Care Unit (ICU) (r=-0.46, p=0.02).</p><p><strong>Conclusions: </strong>In patients with severe symptomatic AS, a smaller aortic valve area at baseline was associated with an early cognitive improvement after transfemoral TAVR. Baseline cognition and the length of stay in the ICU influenced the early functional outcomes.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"311-319"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of multi-plug flow control technique treating high flow cirsoid renal arteriovenous malformations.","authors":"Emre Can Çelebioğlu, Aysegul Coruh Gursoy, Matheus Dabus, Sadık Bilgiç","doi":"10.15386/mpr-2769","DOIUrl":"10.15386/mpr-2769","url":null,"abstract":"<p><strong>Introduction: </strong>Renal arteriovenous malformations (AVMs) are rare vascular lesions mostly diagnosed when they become symptomatic. These lesions can be treated using a variety of endovascular techniques and devices.</p><p><strong>Case report: </strong>We present a 51-year-old male who presented with acute onset right flank pain, hematuria and refractory hypertension. The patient was treated using a multi-plug flow control technique using multiple balloon catheters and microcatheters. Two operators worked synchronously during the procedure using two different dilutions of glue. The patient's symptoms resolved immediately after the embolization and at 1 month follow up the CT demonstrated complete obliteration of the AVM with little renal parenchymal loss. The patient remained clinically asymptomatic at the 6-months follow-up.</p><p><strong>Conclusion: </strong>This case illustrates the feasibility and safety use of synchronous embolization in the treatment of complex renal AVMs.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"398-402"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emotional distress and quality of life in high and moderate penetrance germline mutations carriers diagnosed with breast cancer: a preliminary study.","authors":"Claudiu Ioan Filip, Lorin-Manuel Pîrlog, Andrada-Adelaida Pătrăşcanu, Mariela Sanda Militaru, Irina Iordănescu, George Călin Dindelegan","doi":"10.15386/mpr-2898","DOIUrl":"10.15386/mpr-2898","url":null,"abstract":"<p><strong>Background/objectives: </strong>Genetic testing plays a critical role in breast cancer management by identifying individuals with high or moderate penetrance gene mutations. While clinical implications are well established, less is known about the psychological and quality-of-life impact of different genetic risk levels. This preliminary study aimed to explore whether breast cancer patients with high penetrance mutations experience different levels of distress compared to those with moderate penetrance mutations.</p><p><strong>Methods: </strong>A total of 110 breast cancer patients treated at the Regina Maria Private Health Network in Cluj-Napoca, Romania, were included based on specific eligibility criteria. Participants completed a shortened version of the BREAST-Q questionnaire, focused on core dimensions such as emotional distress, self-concept, appearance, relationships, and financial burden. Descriptive statistics were calculated, and independent t-tests were performed to compare responses between the two genetic risk groups.</p><p><strong>Results: </strong>Patients with high penetrance mutations reported significantly higher distress levels in several domains, including overall emotional distress (p = 0.039), concern for daughters or relatives (p = 0.043), changes in appearance (p = 0.038), and self-concept (p = 0.043). Other factors, such as fear of diagnosis, financial burden, and impact on sexuality, did not show statistically significant differences between groups.</p><p><strong>Conclusions: </strong>This preliminary study suggests that genetic risk classification may influence the psychosocial experience of breast cancer patients, with high penetrance mutation carriers experiencing greater distress in specific areas. These findings highlight the need for personalized psychosocial support based on genetic profiles and warrant further investigation in larger, longitudinal cohorts.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":"98 3","pages":"349-357"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}